Grant Number:	1R50CA221836-01 Interpret this number
Primary Investigator:	Gulati, Roman
Organization:	Fred Hutchinson Cancer Research Center
Project Title:	Advanced Statistical Modeling and Analytics for Prostate Cancer Interventions
Fiscal Year:	2017

PROJECT SUMMARY Developing sound strategies for prostate cancer control requires integrating information from a vast collection of clinical trials and observational studies and developing statistical and computer models to fill in inevitable evidence gaps. Management of prostate cancer is particularly controversial because of the absence of a consensus about optimal screening and treatment approaches. The PI of this application is a member of a team that develops statistical methods and computer models to advance sound prostate cancer policies. This work can only be done by a skilled specialist in cancer surveillance and statistical modeling. It demands expertise in complex statistical computing, which must be meticulously executed and validated, internally and externally. It requires outstanding writing skills to bring projects from the inquiry phase through the publication process, and it requires a proven ability to communicate and collaborate across multidisciplinary teams. The PI of this application has used these skills and others to establish his research group as a leader in prostate cancer modeling and policy. In this application he proposes to use these skills in support of new modeling analyses including (1) targeted screening in high-risk patient subgroups, (2) frameworks for decision making around novel biomarkers for screening and treatment, and (3) advancing methods to estimate overdiagnosis— the detection by screening of cancers that would never be diagnosed otherwise. Additionally, this application will support (1) developing online calculators and decision aids to assist clinicians and policymakers in selecting appropriate recommendations and (2) providing high-quality biostatistical service in a multi-project translational prostate cancer research program. The overarching aim is to optimize interventions to reduce morbidity and mortality from this most common cancer in men.




Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
Authors: Gulati R. , Jiao B. , Al-Faouri R. , Sharma V. , Kaul S. , Fleishman A. , Wymer K. , Boorjian S.A. , Olumi A.F. , Etzioni R. , et al. .
Source: Annals Of Internal Medicine, 2024-06-04 00:00:00.0; , .
EPub date: 2024-06-04 00:00:00.0.
PMID: 38830219
Related Citations

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Authors: Ajkunic A. , Sayar E. , Roudier M.P. , Patel R.A. , Coleman I.M. , De Sarkar N. , Hanratty B. , Adil M. , Zhao J. , Zaidi S. , et al. .
Source: Npj Precision Oncology, 2024-05-17 00:00:00.0; 8(1), p. 104.
EPub date: 2024-05-17 00:00:00.0.
PMID: 38760413
Related Citations

Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
Authors: Lee K.M. , Nelson T.J. , Bryant A. , Teerlink C.C. , Gulati R. , Pagadala M.S. , Tcheandjieu C. , Pridgen K.M. , DuVall S.L. , Yamoah K. , et al. .
Source: Journal Of The National Cancer Institute, 2024-05-08 00:00:00.0; 116(5), p. 753-757.
PMID: 38212986
Related Citations

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Authors: Raychaudhuri R. , Mo G. , Tuchayi A.M. , Graham L. , Gulati R. , Pritchard C.C. , Haffner M.C. , Yezefski T. , Hawley J.E. , Cheng H.H. , et al. .
Source: Jco Precision Oncology, 2024 Apr; 8, p. e2300634.
PMID: 38662984
Related Citations

Projecting the impact of multi-cancer early detection on late-stage incidence using multi-state disease modeling.
Authors: Lange J.M. , Gogebakan K.C. , Gulati R. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2024-03-20 00:00:00.0; , .
EPub date: 2024-03-20 00:00:00.0.
PMID: 38506751
Related Citations

The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
Authors: Wright J.L. , Schenk J.M. , Gulati R. , Beatty S.J. , VanDoren M. , Lin D.W. , Porter M.P. , Morrissey C. , Dash A. , Gore J.L. , et al. .
Source: Cancer, 2024-02-14 00:00:00.0; , .
EPub date: 2024-02-14 00:00:00.0.
PMID: 38353455
Related Citations

ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Authors: Ajkunic A. , Sayar E. , Roudier M.P. , Patel R.A. , Coleman I.M. , De Sarkar N. , Hanratty B. , Adil M. , Zhao J. , Zaidi S. , et al. .
Source: Research Square, 2023-12-19 00:00:00.0; , .
EPub date: 2023-12-19 00:00:00.0.
PMID: 38196594
Related Citations

Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis.
Authors: Park J. , Lim F. , Prest M. , Ferris J.S. , Aziz Z. , Agyekum A. , Wagner S. , Gulati R. , Hur C. .
Source: Scientific Reports, 2023-11-16 00:00:00.0; 13(1), p. 20028.
EPub date: 2023-11-16 00:00:00.0.
PMID: 37973858
Related Citations

Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.
Authors: Gulati R. , Nyame Y.A. , Lange J.M. , Shoag J.E. , Tsodikov A. , Etzioni R. .
Source: Journal Of The National Cancer Institute. Monographs, 2023-11-08 00:00:00.0; 2023(62), p. 212-218.
PMID: 37947332
Related Citations

Revisiting the Standard Blueprint for Biomarker Development to Address Emerging Cancer Early Detection Technologies.
Authors: Etzioni R. , Gulati R. , Patriotis C. , Rutter C. , Zheng Y. , Srivastava S. , Feng Z. .
Source: Journal Of The National Cancer Institute, 2023-11-06 00:00:00.0; , .
EPub date: 2023-11-06 00:00:00.0.
PMID: 37941446
Related Citations

Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
Authors: Patel R.A. , Sayar E. , Coleman I. , Roudier M.P. , Hanratty B. , Low J.Y. , Jaiswal N. , Ajkunic A. , Dumpit R. , Ercan C. , et al. .
Source: The Journal Of Pathology, 2023-10-18 00:00:00.0; , .
EPub date: 2023-10-18 00:00:00.0.
PMID: 37850574
Related Citations

Benefits and harms of prostate specific antigen testing according to Australian guidelines.
Authors: Caruana M. , Gulati R. , Etzioni R. , Barratt A. , Armstrong B.K. , Chiam K. , Nair-Shalliker V. , Luo Q. , Bang A. , Grogan P. , et al. .
Source: International Journal Of Cancer, 2023-10-11 00:00:00.0; , .
EPub date: 2023-10-11 00:00:00.0.
PMID: 37819139
Related Citations

Prostate Cancer Screening in African American Men: A Review of the Evidence.
Authors: Kensler K.H. , Johnson R. , Morley F. , Albrair M. , Dickerman B.A. , Gulati R. , Holt S.K. , Iyer H.S. , Kibel A.S. , Lee J.R. , et al. .
Source: Journal Of The National Cancer Institute, 2023-09-15 00:00:00.0; , .
EPub date: 2023-09-15 00:00:00.0.
PMID: 37713266
Related Citations

Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
Authors: Owens L. , Gogebakan K.C. , Menon U. , Gulati R. , Weiss N.S. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2023-06-01 00:00:00.0; 32(6), p. 741-743.
PMID: 37259797
Related Citations

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Authors: Bhatia V. , Kamat N.V. , Pariva T.E. , Wu L.T. , Tsao A. , Sasaki K. , Sun H. , Javier G. , Nutt S. , Coleman I. , et al. .
Source: Nature Communications, 2023-04-11 00:00:00.0; 14(1), p. 2041.
EPub date: 2023-04-11 00:00:00.0.
PMID: 37041154
Related Citations

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Authors: Sayar E. , Patel R.A. , Coleman I.M. , Roudier M.P. , Zhang A. , Mustafi P. , Low J.Y. , Hanratty B. , Ang L.S. , Bhatia V. , et al. .
Source: Jci Insight, 2023-02-23 00:00:00.0; , .
EPub date: 2023-02-23 00:00:00.0.
PMID: 36821396
Related Citations

Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
Authors: Schweizer M.T. , True L. , Gulati R. , Zhao Y. , Ellis W. , Schade G. , Montgomery B. , Goyal S. , Nega K. , Hakansson A.K. , et al. .
Source: The Journal Of Urology, 2023 Feb; 209(2), p. 354-363.
EPub date: 2023-02-01 00:00:00.0.
PMID: 36621991
Related Citations

Reply by Authors.
Authors: Schweizer M.T. , True L. , Gulati R. , Zhao Y. , Ellis W. , Schade G. , Montgomery B. , Goyal S. , Nega K. , Hakansson A.K. , et al. .
Source: The Journal Of Urology, 2023 Feb; 209(2), p. 362-363.
EPub date: 2023-02-01 00:00:00.0.
PMID: 36621992
Related Citations

Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Authors: Cheng H.H. , Sokolova A.O. , Gulati R. , Bowen D. , Knerr S.A. , Klemfuss N. , Grivas P. , Hsieh A. , Lee J.K. , Schweizer M.T. , et al. .
Source: Jco Precision Oncology, 2023 Jan; 7, p. e2200104.
PMID: 36623239
Related Citations

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Authors: Schweizer M.T. , Gulati R. , Yezefski T. , Cheng H.H. , Mostaghel E. , Haffner M.C. , Patel R.A. , De Sarkar N. , Ha G. , Dumpit R. , et al. .
Source: Prostate Cancer And Prostatic Diseases, 2022-12-23 00:00:00.0; , .
EPub date: 2022-12-23 00:00:00.0.
PMID: 36564459
Related Citations

Reducing Prostate Cancer Overdiagnosis.
Authors: Gulati R. .
Source: The New England Journal Of Medicine, 2022-12-08 00:00:00.0; 387(23), p. 2187-2188.
PMID: 36477037
Related Citations

Clonal Relationships of Adjacent Gleason Pattern 3 and Gleason Pattern 5 Lesions in Gleason Scores 3+5=8 and 5+3=8.
Authors: Bakbak H. , Sayar E. , Kaur H.B. , Salles D.C. , Patel R.A. , Hicks J. , Lotan T.L. , De Marzo A.M. , Gulati R. , Epstein J.I. , et al. .
Source: Human Pathology, 2022-10-26 00:00:00.0; , .
EPub date: 2022-10-26 00:00:00.0.
PMID: 36309296
Related Citations

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Authors: Keeney E. , Sanghera S. , Martin R.M. , Gulati R. , Wiklund F. , Walsh E.I. , Donovan J.L. , Hamdy F. , Neal D.E. , Lane J.A. , et al. .
Source: Pharmacoeconomics, 2022-10-06 00:00:00.0; , .
EPub date: 2022-10-06 00:00:00.0.
PMID: 36201131
Related Citations

Editorial Comment.
Authors: Gulati R. , Nyame Y.A. .
Source: The Journal Of Urology, 2022-09-06 00:00:00.0; , p. 101097JU000000000000283504.
EPub date: 2022-09-06 00:00:00.0.
PMID: 36065679
Related Citations

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Authors: Coleman I.M. , DeSarkar N. , Morrissey C. , Xin L. , Roudier M.P. , Sayar E. , Li D. , Corey E. , Haffner M.C. , Nelson P.S. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2022-07-15 00:00:00.0; 28(14), p. 3127-3140.
PMID: 35552660
Related Citations

Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
Authors: Owens L. , Gulati R. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2022-07-01 00:00:00.0; 31(7), p. 1298-1304.
PMID: 35477176
Related Citations

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.
Authors: Basourakos S.P. , Gulati R. , Vince R.A. , Spratt D.E. , Lewicki P.J. , Hill A. , Nyame Y.A. , Cullen J. , Markt S.C. , Barbieri C.E. , et al. .
Source: Nejm Evidence, 2022 Jun; 1(6), .
EPub date: 2022-05-15 00:00:00.0.
PMID: 35721307
Related Citations

Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas.
Authors: Heijnsdijk E.A.M. , Gulati R. , Lange J.M. , Tsodikov A. , Roberts R. , Etzioni R. .
Source: Jama Health Forum, 2022 05; 3(5), p. e221116.
EPub date: 2022-05-20 00:00:00.0.
PMID: 35977253
Related Citations

Inherited TP53 Variants and Risk of Prostate Cancer.
Authors: Maxwell K.N. , Cheng H.H. , Powers J. , Gulati R. , Ledet E.M. , Morrison C. , Le A. , Hausler R. , Stopfer J. , Hyman S. , et al. .
Source: European Urology, 2022 Mar; 81(3), p. 243-250.
EPub date: 2021-12-01 00:00:00.0.
PMID: 34863587
Related Citations

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
Authors: De Sarkar N. , Dasgupta S. , Chatterjee P. , Coleman I. , Ha G. , Ang L.S. , Kohlbrenner E.A. , Frank S.B. , Nunez T.A. , Salipante S.J. , et al. .
Source: Jci Insight, 2021-12-08 00:00:00.0; 6(23), .
EPub date: 2021-12-08 00:00:00.0.
PMID: 34877933
Related Citations

A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis.
Authors: Psutka S.P. , Gulati R. , Jewett M.A.S. , Fadaak K. , Finelli A. , Legere L. , Morgan T.M. , Pierorazio P.M. , Allaf M.E. , Herrin J. , et al. .
Source: European Urology, 2021-11-30 00:00:00.0; , .
EPub date: 2021-11-30 00:00:00.0.
PMID: 34862099
Related Citations

A Quantitative Framework to Study Potential Benefits and Harms of Multi-cancer Early Detection Testing.
Authors: Jiao B. , Gulati R. , Katki H.A. , Castle P.E. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2021-09-20 00:00:00.0; , .
EPub date: 2021-09-20 00:00:00.0.
PMID: 34548329
Related Citations

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Authors: Sokolova A.O. , Marshall C.H. , Lozano R. , Gulati R. , Ledet E.M. , De Sarkar N. , Grivas P. , Higano C.S. , Montgomery B. , Nelson P.S. , et al. .
Source: The Prostate, 2021-09-13 00:00:00.0; , .
EPub date: 2021-09-13 00:00:00.0.
PMID: 34516663
Related Citations

Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy.
Authors: Etzioni R. , Haffner M.C. , Gulati R. .
Source: European Urology, 2021-08-31 00:00:00.0; , .
EPub date: 2021-08-31 00:00:00.0.
PMID: 34479754
Related Citations

Multi-Cancer Early Detection: Learning from the past to Meet the Future.
Authors: Etzioni R. , Gulati R. , Weiss N.S. .
Source: Journal Of The National Cancer Institute, 2021-08-27 00:00:00.0; , .
EPub date: 2021-08-27 00:00:00.0.
PMID: 34450655
Related Citations

Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Authors: Jiao B. , Gulati R. , Hendrix N. , Gore J.L. , Rais-Bahrami S. , Morgan T.M. , Etzioni R. .
Source: Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, 2021 Aug; 24(8), p. 1111-1117.
EPub date: 2021-04-22 00:00:00.0.
PMID: 34372976
Related Citations

Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study.
Authors: Hendrix N. , Gulati R. , Jiao B. , Kader A.K. , Ryan S.T. , Etzioni R. .
Source: American Journal Of Epidemiology, 2021-05-22 00:00:00.0; , .
EPub date: 2021-05-22 00:00:00.0.
PMID: 34023874
Related Citations

The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
Authors: Nyame Y.A. , Gulati R. , Heijnsdijk E.A.M. , Tsodikov A. , Mariotto A.B. , Gore J.L. , Etzioni R. .
Source: Journal Of The National Cancer Institute, 2021-05-08 00:00:00.0; , .
EPub date: 2021-05-08 00:00:00.0.
PMID: 33963850
Related Citations

When to Discuss Prostate Cancer Screening With Average-Risk Men.
Authors: Gulati R. , Carlsson S.V. , Etzioni R. .
Source: American Journal Of Preventive Medicine, 2021-05-06 00:00:00.0; , .
EPub date: 2021-05-06 00:00:00.0.
PMID: 33966938
Related Citations

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Authors: Graham L.S. , True L.D. , Gulati R. , Schade G.R. , Wright J. , Grivas P. , Yezefski T. , Nega K. , Alexander K. , Hou W.M. , et al. .
Source: The Prostate, 2021-03-23 00:00:00.0; , .
EPub date: 2021-03-23 00:00:00.0.
PMID: 33755225
Related Citations

Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.
Authors: Brady L. , Kriner M. , Coleman I. , Morrissey C. , Roudier M. , True L.D. , Gulati R. , Plymate S.R. , Zhou Z. , Birditt B. , et al. .
Source: Nature Communications, 2021-03-03 00:00:00.0; 12(1), p. 1426.
EPub date: 2021-03-03 00:00:00.0.
PMID: 33658518
Related Citations

Impact of cancer screening on metastasis: A prostate cancer case study.
Authors: Lange J. , Remmers S. , Gulati R. , Bill-Axelson A. , Johansson J.E. , Kwiatkowski M. , Auvinen A. , Hugosson J. , Hu J.C. , Roobol M.J. , et al. .
Source: Journal Of Medical Screening, 2021-02-09 00:00:00.0; , p. 969141321989738.
EPub date: 2021-02-09 00:00:00.0.
PMID: 33563084
Related Citations

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer.
Authors: Nyame Y.A. , Gulati R. , Tsodikov A. , Gore J.L. , Etzioni R. .
Source: Jnci Cancer Spectrum, 2021 Feb; 5(1), p. pkaa098.
EPub date: 2020-10-26 00:00:00.0.
PMID: 33442662
Related Citations

Reconsidering the Trade-offs of Prostate Cancer Screening.
Authors: Shoag J.E. , Nyame Y.A. , Gulati R. , Etzioni R. , Hu J.C. .
Source: The New England Journal Of Medicine, 2020-06-18 00:00:00.0; 382(25), p. 2465-2468.
PMID: 32558473
Related Citations

Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Authors: Nyquist M.D. , Corella A. , Coleman I. , De Sarkar N. , Kaipainen A. , Ha G. , Gulati R. , Ang L. , Chatterjee P. , Lucas J. , et al. .
Source: Cell Reports, 2020-05-26 00:00:00.0; 31(8), p. 107669.
PMID: 32460015
Related Citations

Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
Authors: Gulati R. , Morgan T.M. , A'mar T. , Psutka S.P. , Tosoian J.J. , Etzioni R. .
Source: Journal Of The National Cancer Institute, 2020-04-01 00:00:00.0; 112(4), p. 384-390.
PMID: 31225597
Related Citations

Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
Authors: Corella A.N. , Cabiliza Ordonio M.V.A. , Coleman I. , Lucas J.M. , Kaipainen A. , Nguyen H.M. , Sondheim D. , Brown L.G. , True L.D. , Lee J.K. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2020-04-01 00:00:00.0; 26(7), p. 1667-1677.
EPub date: 2019-12-05 00:00:00.0.
PMID: 31806643
Related Citations

Reply by Authors.
Authors: Gulati R. , Psutka S.P. , Etzioni R. .
Source: The Journal Of Urology, 2020 04; 203(4), p. 842.
EPub date: 2019-12-17 00:00:00.0.
PMID: 31845828
Related Citations

Lifetime benefits and harms of PSA-based risk screening for prostate cancer.
Authors: Heijnsdijk E.A.M. , Gulati R. , Tsodikov A. , Lange J.M. , Mariotto A.B. , Vickers A.J. , Carlsson S.V. , Etzioni R. .
Source: Journal Of The National Cancer Institute, 2020-01-09 00:00:00.0; , .
EPub date: 2020-01-09 00:00:00.0.
PMID: 32067047
Related Citations

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Authors: Schweizer M.T. , Ha G. , Gulati R. , Brown L.C. , McKay R.R. , Dorff T. , Hoge A.C.H. , Reichel J. , Vats P. , Kilari D. , et al. .
Source: Jco Precision Oncology, 2020; 4, p. 382-392.
EPub date: 2020-04-21 00:00:00.0.
PMID: 32671317
Related Citations